Y-mAbs Therapeutics (NASDAQ:YMAB) Now Covered by Analysts at Brookline Capital Management

Brookline Capital Management started coverage on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a research report issued on Thursday,Benzinga reports. The firm set a “buy” rating and a $17.00 price target on the stock. Brookline Capital Management’s price objective indicates a potential upside of 63.78% from the stock’s previous close.

A number of other analysts also recently issued reports on YMAB. Morgan Stanley dropped their price target on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a research report on Tuesday, August 13th. Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday, September 9th. Oppenheimer began coverage on Y-mAbs Therapeutics in a research report on Monday, November 18th. They set an “outperform” rating and a $23.00 price target for the company. BMO Capital Markets dropped their price target on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a research report on Tuesday, August 13th. Finally, Wedbush restated an “outperform” rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a research report on Tuesday, September 10th. One research analyst has rated the stock with a sell rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $20.89.

Y-mAbs Therapeutics Stock Down 1.8 %

Shares of NASDAQ YMAB opened at $10.38 on Thursday. Y-mAbs Therapeutics has a 52 week low of $6.05 and a 52 week high of $20.90. The business has a 50-day simple moving average of $13.33 and a two-hundred day simple moving average of $12.79. The company has a market cap of $464.92 million, a P/E ratio of -19.22 and a beta of 0.61.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its earnings results on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The company had revenue of $18.46 million during the quarter, compared to the consensus estimate of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter in the prior year, the business earned ($0.18) EPS. Equities research analysts anticipate that Y-mAbs Therapeutics will post -0.64 EPS for the current year.

Insiders Place Their Bets

In other news, insider Thomas Gad sold 65,000 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $13.47, for a total transaction of $875,550.00. Following the transaction, the insider now directly owns 97,681 shares of the company’s stock, valued at approximately $1,315,763.07. The trade was a 39.96 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 22.50% of the company’s stock.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Hedge funds have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Y-mAbs Therapeutics during the third quarter valued at approximately $44,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Y-mAbs Therapeutics by 66.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock valued at $113,000 after purchasing an additional 3,416 shares in the last quarter. Intech Investment Management LLC bought a new stake in shares of Y-mAbs Therapeutics during the third quarter valued at approximately $133,000. SG Americas Securities LLC bought a new stake in shares of Y-mAbs Therapeutics during the third quarter valued at approximately $178,000. Finally, Empire Financial Management Company LLC bought a new stake in shares of Y-mAbs Therapeutics during the third quarter valued at approximately $210,000. 70.85% of the stock is owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.